Stroke Journal

FEBRUARY 1, 2024

We aimed to examine the prevalence of VRFs and temporal trends in VRF burden among young patients presenting with IS.Methods:Data was prospectively collected by Get With the Guidelines-Stroke® hospitals participating in the Florida Stroke Registry between January 2010 and December 2022.

Risk Factors 40

Risk Factors Stroke Strokes Coronary Artery Disease 40

DAIC

MARCH 26, 2025

Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Dr. Paddy Barrett

AUGUST 9, 2024

The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.

Dementia 116

Dementia Blood Pressure Obesity Cholesterol 116

DAIC

JANUARY 19, 2024

formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022. This leaves a gap in the care of these patients and increases their risk for heart attack, stroke and heart failure progression. Orchestra BioMed and Medtronic, Inc.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

Journal of the American Heart Association

FEBRUARY 8, 2025

BackgroundClinical trials showed that glucagonlike peptide1 receptor agonist (GLP1RA) significantly improved the control of diabetes and reduced body weight compared with dipeptidyl peptidase 4 inhibitor (DPP4i). Primary outcome was 12month incidence of allcause death. Secondary outcome was hospitalization.

Heart Failure 45

Heart Failure Diabetes Outcomes Hospital 45

The British Journal of Cardiology

AUGUST 6, 2024

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heart failure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.

Inpatient 40

Inpatient Heart Failure Diabetes Hospital 40

All About Cardiovascular System and Disorders

OCTOBER 25, 2023

AF-CHF trial in those with AF and congestive heart failure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heart failure and in those with associated cardiovascular conditions and early AF.

Atrial Fibrillation 52

Atrial Fibrillation Heart Failure Ablation Cardiac Arrest 52

Open Heart

SEPTEMBER 18, 2024

Methods From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. In this study, we explore the use of WCD and evaluate arrhythmic events through comprehensive monitoring.

Defibrillator 52

Defibrillator Sudden Cardiac Death Arrhythmia Outpatient 52

Open Heart

JULY 6, 2023

Methods PubMed, EMBASE and CINAHL were searched from inception to June 2022. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest. Meta-analyses for pooled estimates were performed using DerSimonian and Laird random-effects models.

Kidney Disease 52

Kidney Disease Atrial Fibrillation Heart Failure Risk Factors 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Patients who received thrombolysis and subsequently underwent endovascular therapy for acute ischemic stroke between 2012 and 2022 were included. Median LDL was higher (94 vs 67, p=0.01) and there was a higher rate of diabetes (55.2% vs 40%, p=0.03) and lower rate of atrial fibrillation (12.1% vs 26.6%, p=0.01).

Angioplasty 40

Angioplasty Thrombolysis Hemorrhage Stents 40

Open Heart

MARCH 22, 2025

Objective Historical reductions in cardiovascular disease (CVD) due to lifestyle and treatment improvements are now threatened by factors such as increasing obesity and diabetes, but the relative importance of different risk factors varies by CVD condition. and PAD (RR 1.8).

Cardiovascular Disease 52

Cardiovascular Disease Peripheral Arterial Disease Myocardial Infarction Atrial Fibrillation 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) Of these patients, 79.6%

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Diabetes 52

Dr. Smith's ECG Blog

FEBRUARY 26, 2025

Because previous ischemia induces myocardial preconditioning, decreasing the likelihood of transmural myocardial necrosis and myocardial rupture, patients with evidence of diabetes mellitus, chronic angina or previous MI are less likely to experience a rupture. Cardiology , 114. link] [5] Vega, J. Salinas, G. 2018, July 30).

Chest Pain 88

Chest Pain Pericarditis Myocardial Infarction Dementia 88

Dr. Malcolm Kendrick

OCTOBER 30, 2024

2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M plus drug supply SHARP trial of simvasatin/ezetimibe (2002-2013) Merck/Schering: £40M plus drug supply SHARP3 (2022-23) Boehringer Ingelheim: £1.8M plus drug supply Bayer: £1.8M

Cholesterol 145

Cholesterol Article Research Diet 145